Summary
Mutations of the p53 tumour suppressor gene are infrequent at presentation of both acute myeloblastic leukaemia (AML) and acute lymphoblastic leukaemia (ALL), being found in between 5–10% of AML and 2–3% of ALL. Here we have studied the frequency of detection of p53 mutations at relapse of both AML and B-precursor ALL. In those patients with detectable mutations at relapse we investigated whether the mutation was detectable at presentation and was thus an early initiating event or whether it had arisen as a late event associated with relapse. Bone marrow samples from 55 adults and children with relapsed AML (n = 41) or ALL (n = 14) were analysed for p53 gene alterations by direct sequencing of exons 5–9. For samples where a p53 mutation was found at relapse, analysis of presentation samples was carried out by direct sequencing of the exon involved, or by allele-specific polymerase chain reaction (PCR) if the mutation could not be detected using direct sequencing. A p53 mutated gene was found at relapse in seven out of 55 cases. The frequency was higher in relapsed ALL (four out of 14 cases; 28.6%) compared to AML (three out of 41 cases; 7.3%). In five out of the seven cases presentation samples were available to study for the presence of the mutation. In two out of two AML patients the p53 mutation was detectable in the presentation sample by direct sequencing. In three ALL patients analysis of presentation material by direct sequencing showed a small mutant peak in one case, the other two being negative despite the sample analysed containing > 90% blast cells. However in both of these patients, the presence of p53 mutation was confirmed in the presentation sample using allele-specific PCR. In one of these patients the emergence of a subclone at relapse was confirmed by clonality analysis using IgH fingerprinting. Our results confirm that in ALL p53 mutations are present in a proportion of patients at relapse. Furthermore cells carrying the mutation are detectable at presentation in a minor clone suggesting that p53 mutations in ALL may be a mechanism contributing to disease relapse.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Abo, J., Inokuchi, K., Dan, K. & Nomura, T. (1993). p53 and N-ras mutations in two new leukemia cell lines established from a patient with multilineage CD7-positive acute leukemia. Blood, 82: 2829–2836.
Ahuja, H., Bar-Eli, M., Advani, S. H., Benchimol, S. & Cline, M. J. (1989). Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proc Natl Acad Sci USA 86: 6783–6787.
Baldini, L., Stefano-Fracciolla, N., Cro, L. M., Trecca, D., Romitti, L., Polli, E., Maiolo, A. T. & Neri, A. (1994). Frequent p53 gene involvement in splenic B-cell leukaemia/lymphomas of possible marginal zone origin. Blood, 84: 270–278.
Beishuizen, A., Hahlen, K., Hagemeijer, A., Verhoeven, M. A. J., Hooijkaas, H., Adriaansen, H. J., Wolverstettero, I. L. M., Vanwering, E. R. & Vandongen, J. J. M. (1991). Multiple rearranged immunoglobulin genes in childhood acute lymphoblastic leukemia of precursor B-cell origin. Leukemia 5: 657–667.
Ben-Yehuda, D., Krichevsky, S., Caspi, O., et al (1996). Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood, 88: 3022–3026.
Chim, J. C. S., Coyle, L. A., Yaxley, J. C., Cole-Sinclair, M. F., Cannell, P. K., Hoffbrand, V. A. & Foroni, L. (1996). The use of IgH fingerprinting and ASO-dependent PCR for the investigation of residual disease (MRD) in ALL. Br J Haematol, 92: 104–115.
Coyle, L. A., Papaioannou, M., Yaxley, J. S., Chim, J. S., Attard, M., Hoffbrand, A. V. & Foroni, L. (1996). Molecular analysis of the leukaemic B-cell in adult and childhood acute lymphoblastic leukaemia. Br J Haematol, 94: 685–693.
Diccianni, M. B., Yu, J., Hsiao, M., Mukherjee, S., Shao, L-E & Yu, A. L. (1994). Clinical significance of p53 mutations in relapsed T-cell acute lymphoblastic leukemia. Blood, 84: 3105–3112.
Fenaux, P., Jonveaux, P., Quiquandon, I., Lai, J. L., Pignon, J. M., Loucheux-Lefebvre, M. H., Bauters, F. & Kerckaert, J. P. (1991). p53 gene mutations in myeloid leukemia with 17p monosomy. Blood 78: 1652–1657.
Fenaux, P., Preudhomme, C., Quiquandon, I., Jonveaux, P., Lai, J. L., Vanrumbeke, M., Loucheux-Lefebvre, M. H., Bauters, F., Berger, R. & Kerchaert, J. P. (1992a). Mutations of the p53 gene in acute myeloid leukaemia. Br J Haematol, 80: 178–183.
Fenaux, P., Jonveaux, P., Quiquandon, I., Preudhomme, C., Lai, J. L., Vanrumbeke, M., Loucheux-Lefebvre, M. H., Bauters, F., Berger, R. & Kerckaert, J. P. (1992b). Mutations of the p53 gene in B-cell lymphoblastic acute leukemia: a report on 60 cases. Leukemia, 6: 42–46.
Gaidano, G., Ballerini, P., Gong, J. Z., Inghirami, G., Neri, A., Newcomb, E. W., Magrath, I. T., Knowles, D. M. & Dalla-Favera, R. l. (1991). p53 mutation in human lymphoid malignancies associated with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA, 88: 5413–5417.
Hsiao, M. H., Yu, A. L., Yeargin, J., Ku, D. & Haas, M. (1994). Nonhereditary p53 mutations in T-cell acute lymphoblastic leukemia are associated with the relapse phase. Blood, 83: 2922–2930.
Hu, G., Zhang, W. & Deisseroth, A. B. (1992). p53 gene mutations in acute myelogenous leukaemia. Br J Haematol, 81: 489–494.
Jonveaux, P. & Berger, R. (1991). Infrequent mutations in the p53 gene in primary human T-cell acute lymphoblastic leukemia. Leukemia, 5: 839–840.
Lane, D. P. & Benchimol, S. (1990). p53: oncogene or anti-oncogene? Genes & Development, 4: 1–8.
Larder, B. A., Kohli, A., Kellam, P., Kemp, S. D., Kronick, M. & Henfrey, R. D. (1993). Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature, 365: 671–673.
Lo Coco, F., Gaidano, G., Louie, D. C., Offit, K., Chaganti, R. S. K. & Dalla-Favera, R. (1993). p53 mutations are associated with histologic transformation of follicular lymphoma. Blood, 82: 2289–2295.
Lowe, S. W., Ruley, H. E., Jacks, T. & Housman, D. E. (1993). p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957–967.
Marks, D. I., Kurz, B. W., Link, M. P., Ng, E., Shuster, J. J., Lauer, S. J., Brodsky, I. & Haines, D. S. (1996). High incidence of potential p53 inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis. Blood, 87: 1155–1161.
Martincic, D. & Whitlock, J. A. (1996). Improved detection of p53 point mutations by dideoxyfingerprinting (ddF). Oncogene, 13: 2039–2044.
Mori, N., Wada, M., Yokota, J., Terada, M., Okada, M., Teramura, M., Masuda, M., Hoshino, S., Motoji, T., Oshimi, K. & Mizoguchi, H. (1992). Mutations of the p53 tumour suppressor gene in haematologic neoplasms. Br J Haematol, 81: 235–240.
Murakami, Y., Hayashi, K. & Sekiya, T. (1991). Detection of aberrations of p53 alleles and the gene transcript in human tumor cell lines by single-strand conformation polymorphism analysis. Cancer Res, 51: 3356–3361.
Nakai, H., Misawa, S. H., Toguchida, J., Yandell, D. W. & Ishizaki, K. (1992). Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome. Cancer Res, 52: 6588–6593.
Nishimura, S., Asou, N., Suzushima, H., Okubo, T., Fujimoto, T., Osato, M., Yamasaki, H., Lisha, L. & Takatsuki, K. (1995). p53 gene mutation and loss of heterozygosity are associated with increased risk of disease progression in adult T-cell leukemia. Leukemia, 9: 598–604.
Papaioannou, M., Yaxley, J. C., Hoffbrand, A. V. & Foroni, L. (1997). Oligoclonality in acute lymphoblastic leukaemia (ALL): emergence of minor clones rather than change of clonality at relapse in ALL. Br J Haematol, 97(Suppl 1): 202a
Sander, C. A., Yano, T., Clark, H. M., Harris, C., Longo, D. L., Jaffe, E. S. & Raffeld, M. (1993). p53 mutation is associated with progression in follicular lymphomas. Blood, 82: 1994–2004.
Slingerland, J. M., Minden, M. D. & Benchimol, S. (1991). Mutation of the p53 gene in human acute myelogenous leukemia. Blood 77: 1500–1507.
Sugimoto, K., Hirano, N., Toyoshima, H., Cluiba, S., Mano, H., Takaku, F., Yazaki, Y. & Hirai, H. (1993). Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Blood, 81: 3022–3026.
Sugimoto, K., Toyoshima, H., Sakai, R., Miyagawa, K., Hagiwara, K., Ishikawa, F., Takaku, F., Yazaki, Y. & Hirai, H. (1992). Frequent mutations in the p53 gene in human myeloid leukemia cell lines. Blood, 79: 2378–2383.
Trecca, D., Longo, L., Biondi, A., Cro, L., Calori, R., Grigani, F., Maiolo, A. T., Pelicci, P. G. & Neri, A. (1994). Analysis of p53 gene mutations in acute myeloid leukemia. Am J Hematol, 46: 304–309.
Vogelstein, B. (1990). A deadly inheritance. Nature, 348: 681–682.
Wada, H., Asada, M., Nakazawa, S., Itoh, H., Kobayashi, Y., Inoue, T., Fukumuro, K., Chan, L. C., Sugita, K., Hanada, R., Akuta, N., Kobayashi, N. & Mizutani, S. (1994). Clonal expansion of p53 mutant cells in leukemia progression in vitro. Leukemia, 8: 53–59.
Wada, M., Bartram, C. R., Nakamyra, H., Hachiyam Chen, D. L., Borenstein, J., Hansen-Hagge, T. E., Ludwig, W. D., Reiter, A., Mizoguchi, H. & Koeffler, H. P. (1993). Analysis of p53 mutations in large series of lymphoid hematological malignancies of childhood. Blood, 82: 3163–3169.
Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P. & Fenaux, P. (1994). p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood, 84: 3148–3157.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Zhu, YM., Foroni, L., McQuaker, I. et al. Mechanisms of relapse in acute leukaemia: involvement of p53 mutated subclones in disease progression in acute lymphoblastic leukaemia. Br J Cancer 79, 1151–1157 (1999). https://doi.org/10.1038/sj.bjc.6690183
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690183
Keywords
This article is cited by
-
Significance of genetic polymorphisms in hematological malignancies: implications of risk factors for prognosis and relapse
memo - Magazine of European Medical Oncology (2018)
-
Relapse of Acute Lymphoblastic Leukemia in Children in the Context of Microarray Analyses
Archivum Immunologiae et Therapiae Experimentalis (2011)
-
Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma
Oncogene (2010)
-
Heterogeneity of VH–JH gene rearrangement patterns: an insight into the biology of B cell precursor ALL
Leukemia (2001)
-
Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells
Cell Death & Differentiation (2001)